UNSPSC 51172420: Amylase/dehydrocholic/desoxycholic/homatropine/phenobarbital/protease

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.

UNSPSC 51172420 Amylase/dehydrocholic/desoxycholic/homatropine/phenobarbital/protease is a Commodity code that in recent state and local procurement activity maps to drug testing and specimen collection services rather than pharmaceutical products. Collin County Community Supervision and Corrections Department's RFP 2026-327 illustrates the actual scope: immunoassay screening with LC/MS/MS or GC/MS confirmation, electronic result reporting, alternative testing methodologies including oral fluid and hair testing, and staffing of collection sites. The county is seeking vendors to operate specimen collection facilities and conduct chemical analysis on approximately 25,031 tests annually across five-panel screens, six-panel screens, and ancillary testing. The issuing body is a county corrections and community supervision department, indicating that this code captures forensic and clinical laboratory services procured by law-enforcement and criminal-justice agencies rather than pharmaceutical supply sourcing.

Collin County, Texas represents the only recent posting in the source and issued an RFP with a due date of July 23, 2026, an estimated contract value of $600,000, a two-year base term commencing September 1, 2026, with three optional one-year renewals, and an anticipated award date of August 10, 2026. The vendor must hold lab certification from SAMHSA, TX DPS, or CAP, and pricing is submitted per test with three service models: screening only, confirmation after screening, and screening with automatic confirmation of positives. All pricing must include staffing, freight, delivery, and insurance costs with no additional surcharges permitted. Price redetermination is capped at 3.0 percent annually on medical Consumer Price Index increases and limited to September 1 anniversaries. Evaluation weighting emphasizes vendor understanding and cost equally at 30 points each, with firm qualifications at 25 points and client references at 15 points; optional Phase 2 demonstrations and interviews are worth up to 30 additional points.